A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

NCT05022758 | Completed

• 1 other identifier: 21615
• Study Type: observational
• Target: 45,000
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied. NVAF is a condition in which patients suffer from irregular and often rapid heartbeats which are not caused by a heart valve problem. NVAF can lead to thromboembolism, a condition that happens when a blood clot forms in the body and travels through the blood stream to plug another vessel. To prevent thromboembolism doctors often prescribe a blood thinner medication. In patients with NVAF that receive a blood thinner, it is common that the kidneys' ability to work properly, also called the kidney function, decreases. This may increase the risk of stroke, a condition which occurs when a vessel supplying blood to the brain is blocked and the risk of bleeding. It is therefore important to maintain the kidneys' ability to work properly in these patients who are treated with blood thinners. In the beginning, only one blood thinner that could be given as a tablet by mouth was available. This blood thinner was called warfarin. Over the years, further medications have become available, for example dabigatran or rivaroxaban. There is some evidence that a decrease of the kidney function is more common with warfarin than with dabigatran or rivaroxaban. For other similar new treatments however, evidence is missing or conflicting. There also could be other relevant factors such as the kidney function before the start of treatment or the patient's genes/origin. In this study researchers want to collect more data to compare two different blood thinner medications, rivaroxaban and warfarin. The main goal is to see whether there is a difference between the two treatments regarding the kidneys' ability to work properly. To find this out, the researchers will compare the number of patients in each group who developed chronic kidney disease stage 5 (close to or corresponding to chronic kidney failure), had a kidney transplant or needed to undergo long term dialysis. In addition, data is collected and compared about the patients' age, gender, weight, height and whether they had other related medical problems. This study will collect information from the health records from the Korean National Health Insurance Corporation (NHIC) database. Besides this data collection, no further tests or examinations are planned in this study. Researchers will look at the health information from adult men and women in Korea who were diagnosed with NVAF between January 2013 and December 2017. They will study data of the patients who did not receive any medication with blood thinners in past 24 months before starting rivaroxaban and warfarin treatment between January 2015 and December 2017. They will follow up all the participants until December 2018.

Conditions

Non-valvular Atrial Fibrillation (NVAF)

Keywords

Non-valvular atrial fibrillation (NVAF); Stroke; Rivaroxaban; Systemic embolism

Outcome Measures

Primary Outcomes (1)

• Incidence of kidney failure

  Kidney failure is defined as progression to stage 5 chronic kidney disease (CKD), the need for maintenance dialysis, or having a kidney transplant

  Retrospective analysis from 01-Jan-2015 to 31-Dec-2018

Secondary Outcomes (4)

• Number of participants with ≥ 30% decline in estimated glomerular filtration rate (eGFR)

  Retrospective analysis from 01-Jan-2015 to 31-Dec-2018

• Number of participants with doubling of the serum creatinine level

  Retrospective analysis from 01-Jan-2015 to 31-Dec-2018

• Incidence of Acute kidney injury (AKI)

  Retrospective analysis from 01-Jan-2015 to 31-Dec-2018

• Number of participants with composite renal outcome of ≥ 30% decline in eGFR, doubling of the serum creatinine level and kidney failure

  Retrospective analysis from 01-Jan-2015 to 31-Dec-2018

Study Arms (2)

Participants treated with rivaroxaban

NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation \[OAC\] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.

Drug: Rivaroxaban (Xarelto, BAY59-7939)

Participants treated with warfarin

NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation \[OAC\] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.

Drug: Warfarin

Interventions

Rivaroxaban (Xarelto, BAY59-7939) DRUG

One of NOAC (Non-vitamin K antagonist oral anticoagulants)

Participants treated with rivaroxaban

Warfarin DRUG

One of OAC (Oral anticoagulation therapy)

Participants treated with warfarin

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study is conducted using administrative claims data of the Korean National Health Insurance Service (NHIS) and the linked health check-up database of the National Health Insurance Corporation (NHIC) between 2013 to 2018.

You may qualify if:

• Be ≥20 years of age (legal age in Korea) at the time of anticoagulation initiation
• Have a diagnosis of NVAF (in the 24-months prior to index date)
• Have no record of OAC use (in the 24-months prior to index date)
• Newly initiated on rivaroxaban or warfarin (index date)

You may not qualify if:

• Who have end-stage renal disease or are on dialysis (in the 12-months prior to index date)
• With evidence of valvular heart disease (in the 12-months prior to index date)
• With pulmonary embolism or deep vein thrombosis (within 6 months before index date)
• Who received joint replacement (within 6 months before diagnosis)
• Patients who had previous OAC prescription between 2013 and 2014
• With rivaroxaban doses other than 15 or 20 mg once daily

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Many locations

Multiple Locations, South Korea

Location

Related Links

• Click here for access to information about Bayer's transparency standards and Bayer studies.

MeSH Terms

Conditions

Stroke

Interventions

Rivaroxaban; Warfarin

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Thiophenes; Sulfur Compounds; Organic Chemicals; Morpholines; Oxazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; 4-Hydroxycoumarins; Coumarins; Benzopyrans; Pyrans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2021
• First Posted: August 26, 2021
• Study Start: October 6, 2021
• Primary Completion: October 24, 2022
• Study Completion: October 24, 2022
• Last Updated: October 24, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)